ea0071013 | Bone impact of long-term replacement therapy with recombinant human parathyroid hormone (1-34) in adult patients with hypoparathyroidism evaluated by bone scintigraphy | BES2020
R Fischler
, AL Lecoq
, F Besson
, K Briot
, S Salenave
, C Goujart
, S Leboulleux
, E Carreira
, L Bricaire
, C Chabrolle
, B Corvilain
, C Philippe
, A Linglart
, G Grimon
, P Kamenicky
Introduction: Recombinant human parathyroid hormone (rPTH) (134) is prescribed off-label in France for patients with hypoparathyroidism resistant to conventional therapy. However, the bone impact of this long-term replacement therapy is not well known.Objective: To determine the skeletal impact of chronic treatment with rPTH (134) in patients with hypoparathyroidism.Design: Single-center prospective study. Patients trea...